在超过140万75岁及以上老年人中接种mRNA疫苗降低重型COVID-19风险
研究将1,422,461名75岁及以上已接种mRNA疫苗者与两名同年龄、性别、行政区域和居住类型的未接种者匹配,随访至2021年3月20日。第二剂后第7天起,调整后风险比为0.14(95%CI 0.11-0.17),相当于估计降低86%的COVID-19住院风险。
要点
- 第二剂后第7天起,调整后HR为0.14(95%CI 0.11-0.17)。
- 估计75岁及以上人群COVID-19住院风险降低86%。
- 中位随访38天(IQR 17-54),平均年龄82.4岁(SD 5.7)。
核心结论
- 接种mRNA疫苗与75岁及以上老年人COVID-19住院风险降低相关,调整后HR为0.14(95%CI 0.11-0.17),估计风险降低86%。
研究设计与样本
- 将1,422,461名75岁及以上已接种者与两名同年龄、性别、行政区域和居住类型的未接种者匹配,随访至2021年3月20日。
主要发现
- 平均年龄82.4岁(SD 5.7),中位随访38天(IQR 17-54)。
- 第二剂后第7天起,COVID-19住院的调整后HR为0.14(95%CI 0.11-0.17),估计风险降低86%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized clinical trials have shown mRNA-based vaccines to be 92-95% effective to prevent COVID-19 in adults. We aimed to estimate the impact of vaccination on the risk of severe COVID-19 (requiring hospitalization) in elderly people. Each 1,422,461 vaccinated subject aged 75 or older was matched to two unvaccinated subjects of same age, sex, administrative region, and type of residence. They were followed from date of first injection between 27 December 2020 and 24 February 2021 to 20 March 2021 for COVID-19 hospitalization. Mean age was 82.4 years (SD, 5.7) and median follow-up was 38 days [IQR, 17-54]. Adjusted Hazard Ratio for COVID-19 hospitalization from day 7 after the second dose was estimated at 0.14 (95% confidence interval, 0.11-0.17), i.e. an estimated 86% risk reduction in people aged 75 and older, highlighting the major impact of mRNA vaccination on reducing the risk of COVID-19 among elderly people.
引用
- Botton J, Dray-Spira R, Baricault B, et al. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines. Vaccine. 2021. PMID: 34924220. doi:10.1016/j.vaccine.2021.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。